	intentional omission	10.551932221550498
	deposition testimony	10.501408892508909
	clinical relevance justification	8.804747147207214
	clinically relevant dose justification	6.8569975575665225
	MW chain	5.505558229274471
	European Patent EP	4.351716139220094
	MW requirement	3.5860796425303785
	sulfate heparinic polysaccharide	3.4423893141043393
	polysaccharide chain	3.0579219922820418
	heparinic admixture	2.414249303536731
	MW range	2.152360280514893
	compositional difference	1.954634546494984
	sulfate polysaccharide	1.8312600075461418
¡°	define low molecular weight heparin LMWH mixture	1.7520348664845935
	various dos	1.7328969721673553
	different dos	1.732744072443336
	two dos	1.732667099679651
	number average weight average MW ratio	1.5383972630732825
¡°	Lovenox	1.2021294223715897
¡°	lmwh	1.2012768480270744
	preferred therapeutic dos	1.1755420868797095
	actual dos	1.1554799940716363
	heterogeneous intimate admixture	1.044548931735799
	statistical difference	1.0010404626645377
	statistical analysis	1.0007245874649817
	safe effective dos	0.8750368886813066
	mg dose	0.7215382540079694
	dose independence argument	0.6981287577671037
	inherency	0.6465274934636595
	antithrombotic activity	0.6067858166245708
	thrombose	0.6012781574790184
	hemorrhaging	0.6012781574790184
	inadvertence	0.6012560154197534
	exculpatory testimony	0.6011104898115597
	half life comparison	0.5825693105649475
	half life datum	0.5712705571784017
	different half life	0.5604222977604978
	Cargill	0.5492706319110509
	half life study	0.4571991742078194
	improved half life	0.45155120131022475
	longer half life	0.4492604389557643
	half life improvement	0.44873334016016464
	mean half life	0.44830989104612823
	reasonableness	0.43677335268222395
	oligosaccharide chain	0.4271059888098757
	significantly long half life	0.3741455512807179
	low dosage	0.3392452706146043
	Appx	0.3238360987543322
	low clearance	0.30214685366714433
	facility	0.29634349018081935
	weight average molecular weight	0.2629202551267948
	number average molecular weight	0.2594718641301972
	dose information	0.25926549786422787
	long half life excellent bioavailability high rate	0.2317314669235309
	concealment	0.22864477567447997
	particular dosage information	0.22824209427115907
	Bayer Bioscience N.V.	0.20733042468749377
	rosy picture	0.2065838965181942
	increase residence time	0.20170839246026095
	blood clotting	0.17832397679510173
	serum factor	0.17356099307681247
	weighty uncontroverted evidence	0.14907363164405557
	vivo	0.14827690605197621
	Table X	0.13343472127305656
	misinterpretation	0.12967232366199516
	instant molecular weight requirement	0.12612831247648595
	reduce sensitivity	0.12116171991900264
	Examples	0.11958117695143419
	nondisclosure	0.11440352511632251
	inadvertent error	0.11361108091427459
	prior art molecular weight range	0.10357974087744441
	hour	0.1020075315257752
	statistically significant difference	0.09400367518793556
	negligence	0.09094138852697521
	Table III	0.08956329867030269
	degradation	0.08571545420868887
	third office action	0.07937456476689352
	materiality	0.07603011600717342
	raw datum	0.0716390411752494
	high risk surgery	0.06872862905098331
	plasma	0.06483616183099758
	high intra subject variability	0.06479947349286724
	unenforceability	0.06086710853065294
	first office action	0.05738885106080003
	stability	0.055776123909052976
	therapeutic property	0.05478419651929026
	applicant deceptive intent	0.0546263440286062
	formulation	0.050799284127591555
	compound property	0.04755508488077273
	two compound	0.046841508184094265
	second office action	0.04592081808519645
	Applicant	0.0457694276890555
	applicant material intentional withholding	0.04574799659886253
	misleading way	0.04570075184838165
	unexpected unobvious property	0.043205035098855774
	good efficacy safety ratio	0.04104960615947086
	absorption	0.04090411536007614
	proportion	0.04087508818795988
	applicant allege material intentional withholding	0.038123807304055006
	resistance	0.03695747343791676
	U.S. No. RE	0.03642362856555568
	prior art compound	0.035131109200934534
	inequitable conduct	0.034223998137874814
	second final office action	0.0328316603316564
	Consultants	0.03177357974714005
	Textron	0.02789796538645088
	corroborate evidence	0.027259921942395904
	french chemist	0.026903834915374042
	specified length	0.026741060715932817
	unexpected property	0.02655206928255975
	testing	0.025893471284980717
	five table	0.022208699135530578
	particular therapeutic indication	0.02198858810070897
	egregious error	0.02145647406672158
	paragraph iv certification	0.01892513526341333
	absolutely suggestion	0.01722647267483181
	another declaration	0.016760589508517252
	replacement	0.015267310181276056
	patented composition	0.013518924114900535
	credible explanation	0.01218112729695231
	Central District	0.011409089224520818
	lengthy prosecution	0.011202788878297473
	ANDA	0.01047376689299966
	California	0.010087021566615288
	unexpected result	0.009988145622540348
	prior art composition	0.009422287876898664
	different drug	0.008133087129477981
	industry practice	0.007798858316538648
	preparation	0.006540886945328437
	approval	0.006365055570625349
	examiner anticipation rejection	0.0061644965799366
	final representation	0.005479460229716072
	principle explanation	0.005266788336382995
	pharmaceutical company	0.005157406644310257
	remand	0.004682064981360827
	information material	0.004641295700062927
	material information	0.004641295700062927
	anticipation obviousness portion	0.004060279350523685
	FDA	0.0040566522596549685
	Abbreviated New Drug Application	0.003921921258086205
	abuse	0.0038421259573597813
	accordance	0.0031389515823331874
	affirmative defense	0.0027605774396424858
	definite firm conviction	0.0027018517666112796
	patentability	0.0021149397952813197
	discretion	0.0020495121066786163
	strong inference	0.001455061557602755
	contrast	0.0014157923044490186
	little difference	0.0014107097922972803
	market generic version	0.001240642719582746
	last Office action	0.00124008260839083
	bench trial	0.001226291194882305
	common practice	0.0011542280082432678
	applicant failure	0.001149373038741923
	internal quotation	0.0010003656455773837
	continue application	0.0009449332317284531
	circumstance	0.0008659264248944843
	another reasonable inference	0.0007842045233268138
	PTO	0.0007437624807336554
	complete absence	0.0007239862166496568
	response	0.0006126765048294397
	genuine issue	0.0005751352785824339
	district court inference	0.0004308503610431629
	early opinion	0.0003712304863111458
	district court ultimate holding	0.0003648731570365432
	example	0.00033382212373732795
	allege difference	0.00033211196387276584
	banc	0.00032328676655335713
	various product	0.0002878406134642948
	structure	0.0002720794427727039
	also difference	0.000248368766238926
	Trademark Office	0.0002458404590758226
	clearly erroneous finding	0.00021653987588449926
	original	0.0002137530481423667
	respect	0.0002013119702762435
	summary judgment	0.00010708688096917196
	several reference	7.552209830191533e-05
	lack	6.313343785272434e-05
	background	5.769194347835845e-05
	clear error	5.5895899341366474e-05
	statement	5.3143777252534974e-05
	least four time	5.076974642284097e-05
	prosecution history	4.19423364678645e-05
	particular combination	4.004062221243686e-05
	emphasis	3.964870107498448e-05
	two type	3.0609098454939376e-05
	prior art product	2.8962125743838632e-05
	material fact	2.736069246100321e-05
	jurisdiction	2.4467269292105818e-05
	second time	1.797123433031142e-05
	favor	1.6382855875959362e-05
	relevant part	1.4982986457700054e-05
	skill	1.2459204032776868e-05
	Idaho	1.1873722420174078e-05
	non inventor	1.0811552087194883e-05
	regard	9.729233101118819e-06
	relevant law	9.249416571753979e-06
	determination	9.193903898264226e-06
	district court finding	6.2067304623760275e-06
	record	3.2714792321753786e-06
	present invention	4.515731317780306e-07
	prior evidence	2.8776912229531717e-07
	prior art reference	2.8381027162290684e-07
	support	2.634755941402665e-07
	infringement case	1.2807728220148802e-07
	Court	0.0
	Appeals	0.0
	Inc.	0.0
	Fed	0.0
